二线不同化疗方案治疗小细胞肺癌的疗效和安全性比较

目的 比较二线不同化疗方案治疗小细胞肺癌的疗效和安全性.方法 按照二线治疗方案不同将84例接受二线方案化疗的小细胞肺癌患者分为伊立替康组38例、依托泊苷组24例和紫杉醇/多西他赛组22例,分别给予伊立替康、依托泊苷、紫杉醇/多西他赛治疗.观察3组患者化疗近期疗效、总生存时间(OS)、无进展生存时间(PFS)以及不良反应发生情况.结果 3组患者DCR、ORR比较,差异无统计学意义(P>0.05);3组患者OS和PFS比较,差异无统计学意义(P>0.05).伊立替康组Ⅲ~Ⅳ度腹泻发生率明显高于其他2组,差异具有统计学意义(P<0.05);3组患者Ⅲ~Ⅳ度白细胞减少、贫血、血小板减少、乏力、恶心/呕吐、ALT升高、AST升高发生率比较,差异无统计学意义(P>0.05).结论 不同二线化疗方案对一线化疗失败者效果均确切,生存期相近,不良反应除伊立替康组腹泻发生率稍高外,其他Ⅲ~Ⅳ度不良反应发生率均相近.

Clinical Effects and Security of Different Therapeutic Regimens as Second-line Treatment for Small Cell Lung Cancer

Objective To explore the clinical effects and security of different therapeutic regimens as second -line treat-ment for small cell lung cancer.Methods 84 cases of patients with small cell lung cancer were divided into irinotecan group (38 cases),etoposide group(24 cases),taxol/docetaxel group(22 cases),they were treated by irinotecan,etoposide,taxol/docetaxel respectively.The clinical effects,OS,PFS,side effects were compared.Results There had no significant difference on the DCR , ORR(P>0.05);There had no significant difference in the OS ,PFS(P>0.05);The rate ofⅢ~Ⅳdegree diarrhea for the irino-tecan group were higher than the other group (P<0.05);There had no significant difference in the rate of Ⅲ~Ⅳ degree hypo-leucocytosis,anemia,thrombopenia,feeble,nausea/vomit,ALT increase,AST increase(P>0.05).Conclusion It can lengthen the survival for the patients with small cell lung cancer by different therapeutic regimens as second -line treatment,with similar clinical effects,survival,Ⅲ~Ⅳdegree side effect.